CROSSJECTFRA:74C +0.12%42 PEG Ratio is 0.00 as of Jul. 04, 2026. GuruFocus rates FRA:74C with a GF Score™ of 42/100 and a GF Value™ of €1.11 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 207 Medical Devices & Instruments companies, CROSSJECT ranks worse than 483091.3% on this metric.
PE Ratio without NRI / 5-Year EBITDA Growth Rate*
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, CROSSJECT's PE Ratio without NRI is 0.00. CROSSJECT's 5-Year EBITDA growth rate is 14.10%. Therefore, CROSSJECT's PEG Ratio for today is 0.00.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for CROSSJECT's PEG Ratio or its related term are showing as below:
FRA:74C's PEG Ratio is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.03 * Ranked among companies with meaningful PEG Ratio only.
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
CROSSJECT (FRA:74C) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
CROSSJECT PEG Ratio Related Terms
CROSSJECT PEG Ratio Historical Data
* Premium members only.
The historical data trend for CROSSJECT's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, CROSSJECT's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CROSSJECT PEG Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CROSSJECT's PEG Ratio distribution charts can be found below:
* The bar in red indicates where CROSSJECT's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
CROSSJECT (FRA:74C) has a PEG Ratio of 0.00 as of Jul. 04, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on CROSSJECT and its competitors. According to the industry distribution chart, CROSSJECT ranks #999999 out of 207 companies in the Medical Devices & Instruments industry.
Is CROSSJECT's PEG Ratio too high?
CROSSJECT's current PEG Ratio is 0.00. Based on the distribution chart, CROSSJECT ranks #999999 out of 207 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, CROSSJECT has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CROSSJECT's PEG Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, CROSSJECT ranks #999999 out of 207 companies for PEG Ratio. This places CROSSJECT in the lower half of its industry. The industry median PEG Ratio is 2.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Medical Devices & Instruments company?
The median PEG Ratio among Medical Devices & Instruments companies is 2.03, based on 207 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on CROSSJECT and its competitors. For the Medical Devices & Instruments industry, the median PEG Ratio is 2.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CROSSJECT's current PEG Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CROSSJECT stock overvalued right now?
Based on GuruFocus' analysis, CROSSJECT (FRA:74C) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.11, compared to a current price of €1.66 — trading 49.9% above its estimated fair value. The current PEG Ratio is 0.00. CROSSJECT's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For CROSSJECT (FRA:74C), the current PEG Ratio is 0.00 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CROSSJECT (FRA:74C) Overvalued in 2026?
Based on GuruFocus' analysis, CROSSJECT stock appears to be overvalued.
The current stock price of €1.66 is trading 49.9% above its estimated GF Value™ of €1.11.
GuruFocus considers CROSSJECT to be Significantly Overvalued.
Key valuation signals for FRA:74C:
PEG Ratio: 0.00
GF Value™: €1.11 vs. price of €1.66 (49.9% above fair value)
No single metric tells the full story. See the FRA:74C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:74C has been successfully added to your 
